As of November 8, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Lucid Diagnostics Inc. The largest reported stake is PAVmed Inc.'s, at 27.5%. 2 filings are on record since October 10, 2025 (Schedule 13D/A, February 9, 2026).
Sell to companies like Lucid Diagnostics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Lucid Diagnostics Inc. has 2 Schedule 13D or 13G filings on record since 2025-10-10. 1 holder's latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| PAVmed Inc. | 27.5% | 38,816,903 | SCHEDULE 13D/A, 2026-02-09 | 2026-02-03 |
Holding shares or following this stake? See who's behind Lucid Diagnostics Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Lucid Diagnostics Inc. and the records around it.
The people at Lucid Diagnostics Inc.
- DENNIS MCGRATH is also named on 6 other Form D filings: PAVmed Inc. (Feb 2026), DarioHealth Corp. (Oct 2025), Veris Health Inc. (Jul 2025)
- DENNIS MATHEIS is also named on 3 other Form D filings: DarioHealth Corp. (Oct 2025)
- LISHAN AKLOG is also named on 3 other Form D filings: PAVmed Inc. (Feb 2026), Veris Health Inc. (Jul 2025)
- DEBRA WHITE, MICHAEL GORDON, RONALD SPARKS and SHAUN O'NEIL are also named on 2 other Form D filings: PAVmed Inc. (Feb 2026)
Lucid Diagnostics Inc. elsewhere on the record
Watch Lucid Diagnostics Inc.
Get an email when Lucid Diagnostics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Lucid Diagnostics Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Lucid Diagnostics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lucid Diagnostics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
PAVmed Inc.
The Reporting Person is the parent company of the Issuer. As a result of its ability to vote 27.5% of the Common Stock (and an estimated 26.3% of all the capital stock of the Issuer), the Reporting Person has the power to significantly influence the election of directors and all other matters that would require the vote of the outstanding shares of capital stock of the Issuer. Subject to the restrictions on transfer described in Item 6, the Reporting Person or any of the Principals, respectively, may acquire additional securities of the Issuer and may sell all or a portion of the securities then held in the open market or in privately negotiated transactions, although none of the Reporting Person or the Principals has any present intention to acquire or sell any securities of the Issuer except as described in Item 6 (including pursuant to the Amendment Agreement described in such item). Each of the Reporting Person and each of the Principals, respectively, intends to review its ownership of the Issuer on a continuing basis. Any actions the Reporting Person or any Principal might undertake with respect to the Common Stock may be made at any time and from time to time without prior notice and will be dependent upon the Reporting Person's review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer's business, financial condition, operations and prospects; price levels of the Issuer's securities; general market, industry and economic …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-02-09; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-10 | PAVmed Inc. | 28.3% | SCHEDULE 13D/A |
| 2026-02-09 | PAVmed Inc. | 27.5% | SCHEDULE 13D/A |
Questions about who owns Lucid Diagnostics Inc.
Who owns Lucid Diagnostics Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Lucid Diagnostics Inc.: PAVmed Inc. (27.5%, Schedule 13D/A, filed 2026-02-09).
When did PAVmed Inc. buy into Lucid Diagnostics Inc.?
The filings give report dates, not purchase dates. The earliest filing from PAVmed Inc. on this page is the Schedule 13D/A, filed 2025-10-10, reporting 28.3%; its latest, Schedule 13D/A filed 2026-02-09, reports 27.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Lucid Diagnostics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| December 6, 2024 | Form D, private offering | $21.95M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Lucid Diagnostics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.